Option Care Health Yönetim

Yönetim kriter kontrolleri 2/4

Option Care Health CEO'su John Rademacher, Aug2017 tarihinde atandı, in görev süresi 7.33 yıldır. in toplam yıllık tazminatı $ 16.61M olup, şirket hissesi ve opsiyonları dahil olmak üzere 6% maaş ve 94% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.11% ine doğrudan sahiptir ve bu hisseler € 4.08M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.7 yıl ve 5.9 yıldır.

Anahtar bilgiler

John Rademacher

İcra Kurulu Başkanı

US$16.6m

Toplam tazminat

CEO maaş yüzdesi	6.0%
CEO görev süresi	7.3yrs
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	2.7yrs
Yönetim Kurulu ortalama görev süresi	5.9yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

John Rademacher'un ücretlendirmesi Option Care Health'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$209m
Jun 30 2024	n/a	n/a	US$211m
Mar 31 2024	n/a	n/a	US$273m
Dec 31 2023	US$17m	US$1m	US$267m
Sep 30 2023	n/a	n/a	US$257m
Jun 30 2023	n/a	n/a	US$240m
Mar 31 2023	n/a	n/a	US$159m
Dec 31 2022	US$7m	US$954k	US$151m
Sep 30 2022	n/a	n/a	US$178m
Jun 30 2022	n/a	n/a	US$175m
Mar 31 2022	n/a	n/a	US$173m
Dec 31 2021	US$8m	US$669k	US$140m
Sep 30 2021	n/a	n/a	US$82m
Jun 30 2021	n/a	n/a	US$48m
Mar 31 2021	n/a	n/a	US$9m
Dec 31 2020	US$1m	US$500k	-US$8m
Sep 30 2020	n/a	n/a	-US$42m
Jun 30 2020	n/a	n/a	-US$86m
Mar 31 2020	n/a	n/a	-US$92m
Dec 31 2019	US$856k	US$487k	-US$76m

Tazminat ve Piyasa: John 'nin toplam tazminatı ($USD 16.61M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.94M ).

Tazminat ve Kazançlar: John şirketinin tazminatı %20'den fazla artarken, şirketin kazancı geçen yıl %20'den fazla düştü.

CEO

John Rademacher (57 yo)

7.3yrs

Görev süresi

US$16,613,200

Tazminat

Mr. John C. Rademacher is the President of Option Care Health, Inc. (formerly known as Option Care Enterprises Inc.) and has serves as a Director since 2019. Mr. Rademacher is the Chief Executive Officer o...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
John Rademacher	CEO, President & Director	7.3yrs	US$16.61m	0.11% € 4.1m
Michael Shapiro	Executive VP & CFO	9.3yrs	US$8.32m	0.040% € 1.5m
Luke Whitworth	Chief Operating Officer	1.9yrs	US$3.52m	0.028% € 1.0m
Collin Smyser	General Counsel & Corporate Secretary	2.7yrs	US$2.55m	0.010% € 390.9k
Michael Bavaro	Chief Human Resources & Chief Diversity Officer	2.9yrs	US$2.08m	0.025% € 933.4k
Nicole Maggio	Principal Accounting Officer	less than a year	Veri yok	0.0041% € 154.3k
Brett Michalak	Chief Information Officer	no data	Veri yok	Veri yok
Caroline Budde	Senior VP & Chief Compliance Officer	2.9yrs	Veri yok	Veri yok
Julie Koenig	Senior Vice President of Operations	no data	Veri yok	Veri yok
Chris Grashoff	Chief Growth Officer	2.5yrs	Veri yok	0.0050% € 186.5k
Femi Adewunmi	Chief Medical Officer	no data	Veri yok	Veri yok
Jill Rhodes	Senior VP & Chief Information Security Officer	less than a year	Veri yok	Veri yok

2.7yrs

Ortalama Görev Süresi

45.5yo

Ortalama Yaş

Deneyimli Yönetim: MM6A 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
John Rademacher	CEO, President & Director	5.9yrs	US$16.61m	0.11% € 4.1m
Timothy Sullivan	Independent Director	5.9yrs	US$245.00k	0.012% € 457.0k
Eric Brandt	Director	less than a year	Veri yok	Veri yok
Harry M. Kraemer	Independent Non Executive Chairman of the Board	5.9yrs	US$571.55k	0.19% € 7.2m
David Golding	Independent Director	9.9yrs	US$237.50k	0.063% € 2.4m
Elizabeth Betten	Independent Director	5.9yrs	US$255.00k	0.014% € 531.0k
R. Pate	Independent Director	9.9yrs	US$257.00k	0.021% € 793.3k
Elizabeth Bierbower	Independent Director	2.6yrs	US$248.50k	0.0028% € 103.9k
Barbara Bodem	Independent Director	less than a year	Veri yok	0.0042% € 155.1k
Norman Wright	Independent Director	less than a year	Veri yok	0.0010% € 38.1k
Natasha Deckmann	Independent Director	2.6yrs	US$250.00k	0.0010% € 38.1k

5.9yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MM6A 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.9 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/23 16:03
Gün Sonu Hisse Fiyatı	2024/12/20 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Option Care Health, Inc. 13 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Ishan Majumdar	Baptista Research
Michael Petusky	Barrington Research Associates, Inc.
Joanna Sylvia Gajuk	BofA Global Research

Option Care Health Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Key Executive recently bought €903k worth of stock

Independent Director recently sold €1.3m worth of stock

High number of new directors

Option Care Health, Inc., Annual General Meeting, May 15, 2024

Key Executive recently bought €1.0m worth of stock

Key Executive recently bought €1.7m worth of stock

Recent updates

Key Executive recently bought €903k worth of stock

Option Care Health, Inc. Updates Financial Guidance for the Full Year 2024

Third quarter 2024 earnings released: EPS: US$0.32 (vs US$0.32 in 3Q 2023)

Option Care Health, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Independent Director recently sold €1.3m worth of stock

Option Care Health, Inc. Provides Earnings Guidance for the Full Year of 2024

Investor sentiment improves as stock rises 15%

Option Care Health, Inc. to Report Q2, 2024 Results on Jul 31, 2024

High number of new directors

First quarter 2024 earnings released: EPS: US$0.26 (vs US$0.22 in 1Q 2023)

Option Care Health, Inc. to Report Q1, 2024 Results on Apr 23, 2024

Option Care Health, Inc., Annual General Meeting, May 15, 2024

Key Executive recently bought €1.0m worth of stock

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: US$1.49 (vs US$0.83 in FY 2022)

Option Care Health, Inc. Provides Earnings Guidance for Full Year 2024

Option Care Health, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Now 20% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 16%

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: EPS: US$0.32 (vs US$0.21 in 3Q 2022)

Now 31% undervalued after recent price drop

Option Care Health, Inc. Provides Revenue Guidance for the Full Year 2023

New major risk - Revenue and earnings growth

Option Care Health, Inc. to Report Q3, 2023 Results on Oct 25, 2023

Key Executive recently bought €1.7m worth of stock

New minor risk - Earnings quality

Option Care Health, Inc. Provides Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.64 (vs US$0.19 in 2Q 2022)

Option Care Health, Inc. to Report Q2, 2023 Results on Jul 27, 2023

New minor risk - Share price stability

An unknown buyer acquired 6.004471% stake in Option Care Health, Inc. (NasdaqGS:OPCH) from Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) for approximately $330 million.

Investor sentiment improves as stock rises 16%

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

Option Care Health, Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings released: EPS: US$0.22 (vs US$0.17 in 1Q 2022)

Full year 2022 earnings released: EPS: US$0.83 (vs US$0.78 in FY 2021)

Option Care Health, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Option Care Health, Inc. Appoints Luke Whitworth as Chief Operating Officer

Now 23% undervalued after recent price drop

Now 24% undervalued after recent price drop

Third quarter 2022 earnings released: EPS: US$0.21 (vs US$0.20 in 3Q 2021)

Option Care Health, Inc. Revises Its Revenue Guidance for Full Year 2022

Option Care Health, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Option Care Health, Inc. has completed a Follow-on Equity Offering in the amount of $365.75 million.

Option Care Health, Inc. (NasdaqGS:OPCH) acquired Rochester Home Infusion.

Second quarter 2022 earnings released: EPS: US$0.19 (vs US$0.18 in 2Q 2021)

Option Care Health, Inc. Provides Earnings Guidance for the Full Year 2022

Option Care Health, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Option Care Health, Inc. Elects Anita Allemand, Elizabeth Bierbower, Natasha Deckmann and Aaron Friedman as Directors

First quarter 2022 earnings released: EPS: US$0.17 (vs US$0.016 loss in 1Q 2021)

Now 24% undervalued

Insufficient new directors

Option Care Health, Inc. (NasdaqGS:OPCH) completed the acquisition of Specialty Pharmacy Nursing Network, Inc. for $60 million.

Option Care Health, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Option Care Health, Inc., Annual General Meeting, May 18, 2022

Now 20% undervalued

Option Care Health, Inc. Announces Resignation of Harriet Booker as Chief Operating Officer

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Option Care Health, Inc. (NasdaqGS:OPCH) acquired Wasatch Infusion LLC for $17.8 million.

Option Care Health, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Third quarter 2021 earnings released: EPS US$0.20 (vs US$0.009 in 3Q 2020)

Option Care Health, Inc. has completed a Follow-on Equity Offering in the amount of $247.48 million.

Senior VP of Finance & Chief Accounting Officer Robert Kampstra has left the company

Key Executive recently bought €916k worth of stock

Option Care Health, Inc. has completed a Follow-on Equity Offering in the amount of $364.5 million.

Second quarter 2021 earnings released: EPS US$0.18 (vs US$0.043 loss in 2Q 2020)

Option Care Health, Inc.(NasdaqGS:OPCH) dropped from Russell 2500 Growth Index

Option Care Health, Inc. has completed a Follow-on Equity Offering in the amount of $300 million.